ENTPD1 and neoplasm: CD39 has recently been proposed as a marker of tumor antigen specificity (14, 15), CD103 is a marker of tumor resident memory CD8+ T cells (13, 16) and PD-1 is an immune checkpoint expressed by antigen-experienced CD8+ T cells (17, 18).